Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Mette S. van Ramshorst"'
Autor:
Anna van der Voort, Marte C. Liefaard, Mette S. van Ramshorst, Erik van Werkhoven, Joyce Sanders, Jelle Wesseling, Astrid Scholten, Marie Jeanne T.F.D. Vrancken Peeters, Linda de Munck, Sabine Siesling, Gabe S. Sonke
Publikováno v:
Breast, Vol 65, Iss , Pp 110-115 (2022)
Background: Pathologic complete response (pCR) rates in early stage HER2-positive breast cancer improved after pertuzumab was added to neoadjuvant treatment. However, survival benefit is less-well established and seems mostly limited to node-positive
Externí odkaz:
https://doaj.org/article/8afd7b7a51b54354ada4317477a5ee96
Autor:
Mette S. van Ramshorst, Suzana C. Teixeira, Bas B. Koolen, Kenneth E. Pengel, Kenneth G. Gilhuijs, Jelle Wesseling, Sjoerd Rodenhuis, Renato A. Valdés Olmos, Emiel J. Rutgers, Wouter V. Vogel, Gabe S. Sonke, Marie-Jeanne T. Vrancken Peeters
Publikováno v:
Cancer Imaging, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background 18F-FDG PET/CT can monitor metabolic activity in early breast cancer during neoadjuvant systemic therapy (NST), but it is unknown if the metabolic breast and axillary response differ. We evaluated the correlation between metabolic
Externí odkaz:
https://doaj.org/article/829353bcba674cc7be37d6a13918883f
Autor:
Gabe S. Sonke, Esther H. Lips, Jelle Wesseling, Marie-Jeanne T.D.F. Vrancken Peeters, Erik van Werkhoven, Mette S. van Ramshorst, Liselore M. Janssen, Maartje van Seijen, Tessa G. Steenbruggen
Purpose:In breast cancer, pathologic complete response (pCR) to neoadjuvant systemic therapy (NST) is associated with favorable long-term outcome. Trastuzumab emtansine as additional adjuvant therapy improves recurrence-free survival of patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e0a41a4bb2b820bc4a2e4a6db486b08
https://doi.org/10.1158/1078-0432.c.6528600.v1
https://doi.org/10.1158/1078-0432.c.6528600.v1
Autor:
Gabe S. Sonke, Esther H. Lips, Jelle Wesseling, Marie-Jeanne T.D.F. Vrancken Peeters, Erik van Werkhoven, Mette S. van Ramshorst, Liselore M. Janssen, Maartje van Seijen, Tessa G. Steenbruggen
Supplementary data to Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MJTDF, et al. Prognostic value of residual disease after neoadjuvant therapy in HER2-positive breast cancer evaluated by Residual Can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::224c2b23ffd5fa08d72189ad6b06b753
https://doi.org/10.1158/1078-0432.22473774.v1
https://doi.org/10.1158/1078-0432.22473774.v1
Autor:
Gabe S. Sonke, Esther H. Lips, Jelle Wesseling, Marie-Jeanne T.D.F. Vrancken Peeters, Erik van Werkhoven, Mette S. van Ramshorst, Liselore M. Janssen, Maartje van Seijen, Tessa G. Steenbruggen
Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::172b0a66db849834241fcde82a58d60d
https://doi.org/10.1158/1078-0432.22473777.v1
https://doi.org/10.1158/1078-0432.22473777.v1
Autor:
Anna van der Voort, Mette S. van Ramshorst, Rob Kessels, Ingrid A. Mandjes, Inge Kemper, Mariëtte J. Agterof, Wim A. van der Steeg, Joan B. Heijns, Marlies L. van Bekkum, Ester J. Siemerink, Philomeen M. Kuijer, Astrid Scholten, Jelle Wesseling, Marie-Jeanne T.F.D. Vrancken Peeters, Ritse M. Mann, Gabe S. Sonke
Publikováno v:
Cancer Research. 83:PD18-06
Background pCR rates in stage II – III HER2-positive breast cancer have greatly improved since the addition of HER2 targeted agents to neoadjuvant chemotherapy and are associated with excellent long-term survival. While longer treatment regimens in
Autor:
Marte C. Liefaard, Mette S. van Ramshorst, Marie-Jeanne T. F. D. Vrancken Peeters, Anna van der Voort, Linda de Munck, Jelle Wesseling, Erik van Werkhoven, Gabe S. Sonke, A.N. Scholten
Publikováno v:
Cancer Research. 81:PS10-07
Background Pertuzumab greatly improves pathologic complete response (pCR) rates in early stage HER2-positive breast cancer. Long-term benefit of pertuzumab, however, is less well established, as follow-up of the NEOSPHERE and APHINITY trials did not
Autor:
Tessa G Steenbruggen, Gabe S. Sonke, Erik van Werkhoven, Sabine C. Linn, Sabine Siesling, Marleen Kok, Vincent O. Dezentjé, Mette S. van Ramshorst
Publikováno v:
European journal of cancer, 135, 66-74. Elsevier
European Journal of Cancer, 135, 66-74. Elsevier Limited
European Journal of Cancer, 135, 66-74. Elsevier Limited
Background Recommendations on adjuvant chemotherapy in pT1N0M0 triple-negative breast cancer (TNBC) differ among international guidelines owing to lack of randomized trial data. We evaluated associations of adjuvant chemotherapy with a long-term outc
Autor:
Mette S. van Ramshorst, Aafke H. Honkoop, Vincent O. Dezentjé, Marie-Jeanne T. F. D. Vrancken Peeters, Caroline M.P.W. Mandigers, Sabine C. Linn, Agnes J. van de Wouw, Gabe S. Sonke, I.A.M. Mandjes, Erik van Werkhoven, Anna van der Voort, Jelle Wesseling, Inge Kemper, Laurence J. C. van Warmerdam, Lidwine W. Tick, Irma M. Oving
Publikováno v:
The Lancet Oncology. 19:1630-1640
Summary Background The optimal chemotherapy backbone for dual HER2 blockade in the neoadjuvant setting for early breast cancer is unknown. We investigated whether the addition of anthracyclines would improve pathological complete response compared wi
Autor:
Marie-Jeanne T. F. D. Vrancken Peeters, Emma J. Groen, Mette S. van Ramshorst, Frederieke van Duijnhoven, Ritse M. Mann, Esther H. Lips, Jelle Wesseling, Gabe S. Sonke, Michael Schaapveld, Marieke E. M. van der Noordaa
Publikováno v:
Breast Cancer Research and Treatment, 189, 213-224
Breast Cancer Research and Treatment, 189, 1, pp. 213-224
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 189, 1, pp. 213-224
Breast Cancer Research and Treatment
Purpose The presence of extensive ductal carcinoma in situ (DCIS) adjacent to HER2-positive invasive breast cancer (IBC) is often a contra-indication for breast-conserving surgery, even in case of excellent treatment response of the invasive componen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf29fcec7f5f5dd928682cd323e1e44
http://hdl.handle.net/2066/238668
http://hdl.handle.net/2066/238668